It has been said that the diagnosis of Alzheimer's disease enters the era of biomarkers. These two biomarkers, amyloids, and taus, defines Alzheimer's disease. In this presentation, Dr. Kai Wang, Senior Director of Biomarker Services at Frontage Laboratories, Inc, focuses on highly sensitive protein biomarker assays developed and validated at a testing laboratory and their application for the diagnosis of Alzheimer's disease.

Accumulation of dermatan sulfate (DS) in tissue and body fluid leads to mucopolysaccharidosis II (MPS II) disorder. The study aims to develop an LC-MS/MS assay to measure DS in human cerebrospinal fluid (CSF) as a biomarker.

At Frontage, we provide comprehensive central lab services, including a range of laboratory testing, histology and pathology services, sample management, and global distribution. See our brochure about next-generation central lab services.